Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat
Objective To study the impact of hyperuricemia on clinical presentation, severity, and associated comorbidities of psoriatic arthritis (PsA). Methods Retrospective bicentric case–control study performed in Strasbourg and Colmar, France, from 2009 to 2019. Patients with PsA (according to ICD-10 codin...
Saved in:
| Published in: | Clinical rheumatology Vol. 41; no. 5; pp. 1421 - 1429 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Cham
Springer International Publishing
01-05-2022
Springer Nature B.V |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective
To study the impact of hyperuricemia on clinical presentation, severity, and associated comorbidities of psoriatic arthritis (PsA).
Methods
Retrospective bicentric case–control study performed in Strasbourg and Colmar, France, from 2009 to 2019. Patients with PsA (according to ICD-10 coding) and at least one available serum urate (SU) measurement were included. Demographic, comorbidities, clinical, and radiographic data were collected. Hyperuricemia was defined as SU level ≥ 360 µmol/L.
Results
We included 242 patients: 73 (30.2%) had hyperuricemia and 15 (6.2%) met 2015 ACR/EULAR criteria for gout. On univariate analysis, as compared with normo-uricemic patients, hyperuricemic patients were more frequently male (72.6% vs 39.1%,
p
= 1.6 × 10
−6
) with higher body mass index (30.9 vs 28.7 kg/m
2
,
p
= 0.015) and more comorbidities (Charlson comorbidity index: 2.6 vs 1.8,
p
= 0.005). PsA started at an older age (47.5 vs 43 years,
p
= 0.016) was more polyarticular (56.2% vs 41.9%,
p
= 0.049) than axial (9.6% vs 22.8%,
p
= 0.019) and more destructive (52.8% vs 37.4%,
p
= 0.032). PsA patients with joint destruction more frequently had hyperuricemia than did others (37.6% vs 25.8%,
p
= 0.047). Multivariable analysis confirmed the association of hyperuricemic PsA with peripheral joint involvement (odds ratio 2.98; 95% confidence interval 1.15–7.75;
p
= 0.025) and less good response to treatment (0.35; 0.15–0.87;
p
= 0.024).
Conclusion
Patients with hyperuricemic PsA show poorer response to PsA treatment and have more peripheral and destructive joint damage than normo-uricemic patients.
Key Points
•
Gout and psoriatic arthritis (PsA) can co-exist in the same patient.
•
Monosodium urate crystals might have a deleterious impact on PsA.
•
Hyperuricemic PsA is more polyarticular, less frequently axial, and more destructive than normo-uricemic PsA.
•
PsA with hyperuricemia should lead to more personalized medicine. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 0770-3198 1434-9949 |
| DOI: | 10.1007/s10067-022-06061-x |